As MYC is such a ubiquitous oncogenic driver, we presume that heterogeneity within the MYC-low tumours or alternative mechanisms for activation of the MYC-driven transcriptional program are more likely reasons for this difference, rather than MYC not being a DNA-binding factor driving malignancy. The gene discussed is MYC; the disease is neoplasm.